Navigation Links
Valeant Pharmaceuticals Announces Management Change
Date:9/13/2012

MONTREAL, Sept. 13, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that Rajiv De Silva, Valeant's President and Chief Operating Officer of Specialty Pharmaceuticals, will be leaving the Company to pursue other interests. Mr. De Silva will remain with the Company through the remainder of the year, when the integration planning efforts related to its announced acquisition of Medicis Pharmaceutical Corporation (NYSE: MRX) are expected to have been completed.  Mr. De Silva will be a core member of the team leading these integration planning efforts. In addition, we expect that a number of Medicis executives would accept positions with Valeant after the acquisition has been completed.

"The Board of Directors and I appreciate the significant contributions Rajiv has made these past few years since joining me on this journey to create a new pharmaceutical operating model," said J. Michael Pearson, chairman and chief executive officer.  "Under Rajiv's leadership, we have become a leader in the U.S. dermatology space and transformed our operations in Canada and Australia. And although his leadership will be missed, the company has created and developed a strong management team with Rajiv's assistance that I am confident will lead us successfully through this transition period and into the future."

"The last four years at Valeant has been an extraordinary experience," said Rajiv De Silva.  "It has been a privilege to work with Mike, other members of the management team, and the Board on this journey."

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology , neurology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Caution Regarding Forward-Looking Information

This press release may contain forward-looking statements, including, but not limited to, statements regarding the integration of Valeant and Medicis, the timing of certain executives remaining with Valeant or joining Valeant, and the operation of the specialty pharmaceuticals organization. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and other risks and uncertainties detailed from time to time in the Company's filings with the SEC and the Canadian Securities Administrators \, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
2. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
3. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
4. Valeant Pharmaceuticals To Host Investor Day
5. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
6. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
7. Isis Pharmaceuticals Completes Redemption Of 2 5/8% Convertible Subordinated Notes Due 2027
8. Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
9. Gerri Henwood Joins Actinium Pharmaceuticals as Chief Development Officer
10. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
11. Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2020)... (PRWEB) , ... May 26, 2020 , ... ... announced its partnership with dicentra , seeking to provide them with revolutionary ... with its clinical trial management platform, an end-to-end solution that enables onboarding, scheduling, ...
(Date:5/21/2020)... (PRWEB) , ... May 21, 2020 , ... ... Medical Workers , Latham to help manufacture 25,000 polymer film gowns that will ... largest manufacturer of inground residential swimming pools and accessories, is excited to give ...
(Date:5/21/2020)... (PRWEB) , ... May 21, 2020 , ... ... U.S. healthcare providers nationwide began implementing telehealth solutions in order to continue seeing ... from Updox , the place for virtual care and complete healthcare communications, ...
Breaking Medicine Technology:
(Date:5/26/2020)... Mass. (PRWEB) , ... May 26, 2020 , ... Today ... Self-Assessment , a free online tool that will help business owners and leaders assess ... reopen and ramp up. This latest offering from TRC is intended to assist business ...
(Date:5/25/2020)... Calif (PRWEB) , ... May 23, 2020 , ... Winemaker ... the moment. We wanted to present something whimsical and delicious in these complicated times,” ... Red Wine Blend ($34.99) and 2018 Grenache ($24.99). The Chardonnay and Red Wine Blend ...
(Date:5/21/2020)... ... May 21, 2020 , ... Summit Medical , an ... over one million FDA-compliant face shields — designed, engineered and manufactured in the ... need for personal protective equipment (PPE) for both front-line health care workers and ...
(Date:5/21/2020)... ... , ... A Safe Haven Foundation (ASHF) has been selected as one of ... Resilience Fund. The fund was created in March to help nonprofits with their immediate ... to vulnerable populations in hard-hit communities. , “We are humbled and honored to ...
(Date:5/21/2020)... ... 2020 , ... ESO , the leading data and software company serving ... 2020 ESO Fire Service Index . The Index looks at key trends across ... turnout time and travel time, the most common property types visited and estimated property ...
Breaking Medicine News(10 mins):